IW 360

April 19, 2026 Viktor Zarev 0 min read
  1. FDA reclassifies peptides and sends telehealth stocks soaring.
  2. Trump taps former public health leader Erica Schwartz to run CDC.
  3. CMS proposes repeal of breakthrough device pathway.
  4. HHS brings on first affordability czar.
  5. Inside Epic’s confidential vendor services agreement.
  6. 37 leading health systems ranked by operating margin.
  7. Amazon to stock Lilly’s new weight-loss pill at U.S. kiosks.
  8. Premier Health names new chief digital information officer.
  9. 83 health systems ranked by annual revenue.
  10. Beyond March Madness: athletics boost academic health system marketing.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Heart Failure May 21, 2026

Inflammation’s Prevalence and Role in Heart Failure May 21, 2026

Heart failure inflammation might actually be an underrecognized therapeutic target, after results from the POSEIDON registry analysis found that systemic inflammation is present in nearly half of heart failure patients, regardless of ejection fraction.

Structural Heart May 18, 2026

Cardiac Wire’s State of The Transcatheter Valve May 18, 2026

It might feel like a transcatheter alphabet soup out there with all of the valve interventions that have come out in the last few years, but Cardiac Wire is here to help make sense of it all.

Structural Heart May 14, 2026

The Young TAVR Trend is Stabilizing May 14, 2026

Despite a TAVR popularity surge in recent years, a Vizient registry analysis suggests the procedure’s prevalence has stabilized in patients under 65, but there’s still significant debate on whether the young patient TAVR rate is appropriate.